Avacta Group (AVCT)
18/01/2018 - 07:31 StockMarketWire
Avacta expects revenue, operating losses and cash balances for the six months ending 31 Jan to be in line with market forec...
15/01/2018 - 10:58 RNS
RNS Number: 8785B Avacta Group PLC 15 January 2018 Hardman Research: Affimer Drug Conjugates a reality Affimer Drug Conjugates a reality - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which...
15/01/2018 - 07:04 StockMarketWire
Avacta Group and Glythera have agreed the terms of a licensing deal which will allow them to develop drug conjugates u...
15/01/2018 - 07:00 RNS
RNS Number: 7915B Avacta Group PLC 15 January 2018 15 January 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership Successful proof-of-concept study leads to Affimer drug conjugate development partnership Affimers shown to have key ...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment